Results 71 to 80 of about 14,451 (187)

How Escherichia coli Circumvent Complement-Mediated Killing

Frontiers in Immunology, 2017
Complement is a crucial arm of the innate immune response against invading bacterial pathogens, and one of its main functions is to recognize and destroy target cells.
Angela S. Barbosa, Afonso G. Abreu, Afonso G. Abreu   +2 more
doaj   +1 more source

Salamander–Batrachochytrium salamandrivorans Interactions Through Dual Transcriptomics

Ecology and Evolution, Volume 16, Issue 7, July 2026.
Using dual transcriptomics, this study reveals how salamanders defend against an emerging pathogen and how the pathogen infects multiple hosts, uncovering a novel calmodulin‐mediated virulence pathway. These mechanistic insights connect molecular responses to host susceptibility, advancing our understanding of the potential impacts of disease on ...
María Torres‐Sánchez
wiley   +1 more source

Complement Inhibition in the Clinic: Are We Doing Enough to Protect Patients From Infection?

European Journal of Immunology, Volume 56, Issue 7, July 2026.
Excessive complement activation is implicated in a broad range of diseases. Therapeutic approaches targeting the complement cascade, from pathway‐selective inhibition to terminal blockade, can effectively control disease activity. However, increasing degrees of complement inhibition are associated with a heightened susceptibility to bacterial, viral ...
Serena Bettoni, Ebba Qviberg, Edward Chaloner, Hayley Lavender, Maisem Laabei   +4 more
wiley   +1 more source

Complement Factor H‐Based Therapeutics: A Comprehensive Overview

European Journal of Immunology, Volume 56, Issue 7, July 2026.
Complement factor H is a central regulator of the complement system and thus a target for therapeutic intervention. In this review, we provide an overview of past and current factor H‐based therapeutic concepts and modalities to treat complement‐mediated diseases.
Sebastiaan M. W. R. Hamers, Emmy J. Buter, Richard B. Pouw   +2 more
wiley   +1 more source

Complement Gene Variants Define the Conformational Dynamics of C3 Convertase

European Journal of Immunology, Volume 56, Issue 7, July 2026.
Multidisciplinary data have significantly advanced our understanding of C3bBb molecular dynamics. This review specifically contextualizes the functional impact of disease‐associated genetic variants, demonstrating that clinical genetics not only supports the current C3bBb model but also provides novel insights into previously undefined molecular ...
Héctor Martín Merinero, Seth J. Welsh, Zhen Xu, Richard J. H. Smith, Yuzhou Zhang   +4 more
wiley   +1 more source

Treatment of Plasmodium falciparum merozoites with the protease inhibitor E64 and mechanical filtration increases their susceptibility to complement activation.

PLoS ONE, 2020
Plasmodium falciparum malaria killed 451,000 people in 2017. Merozoites, the stage of the parasite that invades RBCs, are a logical target for vaccine development.
José A Stoute, Mary E Landmesser, Sergei Biryukov   +2 more
doaj   +1 more source

Microglial Pruning of Excitatory Synapses in the Hippocampus Is Complement C3‐Independent in Physiological and Neuroinflammatory States

Glia, Volume 74, Issue 7, July 2026.
In development, microglia engulfment of hippocampal excitatory synapses is unperturbed in C3‐lacking mice. Peripheral inflammation induces a neuroinflammatory phenotype and synapse loss in the hippocampus independent of complement cascade activation. ABSTRACT A key feature of brain development is the refinement of exuberant synapses, known as synapse ...
Eric W. Salter, Ashish Kadia, Lijia Zhang, Jonathan S. Thacker, Sun‐Lim Choi, Liam T. Ralph, Gang Lei, Fuzi Jin, John Georgiou, Graham L. Collingridge   +9 more
wiley   +1 more source

Efficacy of high‐frequency low‐dose rituximab and acalabrutinib in chronic lymphocytic leukemia

HemaSphere, Volume 10, Issue 7, July 2026.
Abstract Anti‐CD20 monoclonal antibodies (mAbs) are effective but not curative treatment for chronic lymphocytic leukemia (CLL). To study rituximab efficacy, we examined serial blood samples from CLL patients receiving initial monotherapy with high‐frequency low‐dose (HFLD) rituximab for 1 week followed by the addition of acalabrutinib.
Charles C. Chu, Clare B. Heffernan, Nydia C. Jaimes‐Delgadillo, Christine A. Herne, Jennifer E. Bruno, Andrea M. Baran, John M. Ashton, Timothy R. Mosmann, Paul M. Barr, Ronald P. Taylor, Michael R. Elliott, Clive S. Zent   +11 more
wiley   +1 more source

Factor H-related protein 1 promotes complement-mediated opsonization of Pseudomonas aeruginosa

Frontiers in Cellular and Infection Microbiology
Pseudomonas aeruginosa is an important human opportunistic pathogen responsible for a wide range of infections. The complement system is the main early host defense mechanism to control these infections. P.
Alex González-Alsina, Héctor Martín-Merinero, Margalida Mateu-Borrás, María Verd, Antonio Doménech-Sánchez, Joanna B. Goldberg, Santiago Rodríguez de Córdoba, Sebastián Albertí   +7 more
doaj   +1 more source

Enzymatic Reactions and Detection of C3 Cleavage Fragments

Bio-Protocol, 2014
The complement component C3 is the major effector molecule of the complement system. C3 circulates in the blood and interstitial fluids as pro-enzyme and is activated by enzymatic cleavage into a C3a portion, a classic anaphylatoxin that functions as ...
Claudia Kemper, Martin Kolev
doaj   +1 more source